Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Midbrain dopamine D2/3 receptor binding in schizophrenia.

Heli Tuppurainen1, Jyrki T Kuikka, Mikko P Laakso

  • 1Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, 70240, Kuopio, Finland. heli.tuppurainen@niuva.fi

European Archives of Psychiatry and Clinical Neuroscience
|June 20, 2006
PubMed
Summary

This study found lower dopamine D(2/3) receptor densities in the midbrain of schizophrenia patients. These findings suggest altered midbrain dopamine activity contributes to schizophrenia symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized?

Schizophrenia bulletin·2025
Same author

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force.

European psychiatry : the journal of the Association of European Psychiatrists·2025
Same author

Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia.

Journal of psychiatry & neuroscience : JPN·2024
Same author

Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.

Schizophrenia research·2024
Same author

Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2024
Same author

Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: A nationwide register-linkage study from Sweden.

Schizophrenia research·2024

Area of Science:

  • Neuroscience
  • Psychiatry
  • Radiology

Background:

  • Dopaminergic transmission dysregulation in the midbrain and thalamus is implicated in schizophrenia.
  • Understanding dopamine D(2/3) receptor alterations is crucial for schizophrenia research.

Purpose of the Study:

  • To investigate dopamine D(2/3) receptor density changes in the midbrain and thalamus of drug-naïve schizophrenia patients.
  • To correlate receptor binding with schizophrenic symptom severity.

Main Methods:

  • Utilized single-photon emission tomography (SPECT) with the ligand [(123)I]epidepride.
  • Scanned six neuroleptic-naïve schizophrenia patients and seven healthy controls.
  • Assessed symptoms using the Positive and Negative Syndrome Scale (PANSS).

Related Experiment Videos

Main Results:

  • Significantly lower dopamine D(2/3) receptor binding was observed in the midbrain of schizophrenia patients compared to controls (P=0.02).
  • No significant difference in thalamic D(2/3) receptor binding was found between groups.
  • Negative correlations were noted between thalamic D(2/3) receptor binding and general psychopathological symptoms (r=-0.78 to -0.92).

Conclusions:

  • Altered dopaminergic activity in the midbrain is implicated in schizophrenia.
  • Thalamic dopamine D(2/3) receptor binding may correlate with overall symptom severity in schizophrenia.